Insulet Corporation — Medical Devices. Scored on the same transparent 7-signal model behind the daily rankings.
★
PODD
Insulet Corporation · Medical Devices
FCF$416mC
Rev+30.7%A
D/E0.78C+
P/E37.0xC+
PEG1.41B
79.5Score
$158.29$11.0B
1Y Target$239.42Analyst consensus · 24 analysts
5Y Target$350.53Compound horizon
10Y Target$519.99Long-dated conviction
FCF$416mTTMC
FCF $416m — modest; watch for margin expansion
Rev+30.7%TTM YoYA
Revenue +30.7% — hypergrowth, top decile
D/E0.78C+
D/E 0.78 — above the Healthcare debt median (≈75th pctile)
P/E37.0xC+
P/E 37.0 — above the Healthcare median (≈75th pctile)
PEG1.41B
PEG 1.41 — acceptable premium for growth
Forward price target — the 1-year figure is the analyst consensus where the stock is covered; the 5- and 10-year figures compound our earnings estimate from there. The DCF below is a separate cross-check on intrinsic value (what it's worth today), not another target.
Quality-growth score · 79.5
Quality0.75
Growth1.00
Value0.67
Entry · Margin of safety
52-week rangeNear 52-week low
55% off the 12-month high
vs DCF fair value23% aboveest. fair value ~$128
Quality signals · context only
Gross profitability69% · Agross profit ÷ total assets (Novy-Marx)
ROIC14.9% · B+return on invested capital — not score-weighted
Why now
Insulet Corporation is a high-quality compounder poised for continued expansion, driven by the strong adoption of its Omnipod 5 automated insulin delivery system in the critical diabetes management market. The company's impressive 30.7% revenue growth, coupled with robust $416m in free cash flow, demonstrates both market capture and financial strength. With the stock trading near its 52-week low of $138.79 and a consensus 1-year analyst target of $239.42, the market is underpricing the persistent demand for innovative, user-friendly insulin delivery solutions.
Moat
Insulet's durable edge stems from its proprietary Omnipod platform, particularly the Omnipod 5's embedded AID algorithm and seamless integration with third-party continuous glucose monitors. This technology creates significant switching costs for users who rely on its convenience and efficacy for daily diabetes management, making it difficult for competitors to dislodge. The company's exceptional 23.2% Return on Equity reflects its category leadership and pricing power within the automated insulin delivery system market, a testament to its innovation and patient loyalty.
Risk
The primary bear case for Insulet centers on its elevated valuation and potential competitive pressures in the rapidly evolving medical device sector. A P/E TTM of 36.8 suggests significant future growth is already priced in, leaving little room for execution missteps or increased competition from alternative insulin delivery systems. The relatively high debt-to-equity ratio of 0.78, while manageable, could become a concern if revenue growth for the Omnipod 5 decelerates faster than anticipated, signaling market saturation or a superior competitive offering.
Horizon
1-3 yr $239.42 (24-analyst consensus) — fundamentals + valuation re-rating. 5 yr $350.53 at ~17% CAGR — compounding case rests on the competitive position widening. 10 yr $519.99 if current growth sustains into durable earnings power.
Not investment advice. The Bull Rankings publishes a quantitative ranking model and accompanying analysis for general informational purposes only. Nothing on this page is a recommendation to buy, sell, or hold any security; nothing is personalized to your circumstances, risk tolerance, or tax situation. Investing carries the risk of loss — invest at your own risk and consider consulting a licensed financial professional before acting on anything you read here. See terms and methodology for full disclosures.
Position sizing · PODD
$
%
%
Shares to buy
12
Position size
$1,899
3.8% of portfolio
Stop price
$118.72
25% below $158.29
$ at risk if stopped
$474.87
budget $500.00 · 1% of portfolio
Math only — share count is floor(portfolio × risk% ÷ (price × stop%)). Doesn't account for commissions, slippage, gap risk, or position-correlation across your book. Inputs persist locally; never sent to the server. Not investment advice.
Insulet Corporation (PODD) is a Medical Devices company that scores 79.5 out of 100 on the Bull Rankings quality-growth model — a strong reading. The score blends three pillars — quality (durable returns, healthy margins, low leverage), growth (revenue and earnings), and value (valuation versus sector peers) — into one number, refreshed daily; it is a screen, not a buy recommendation.
Its strongest graded signals are Rev (A). On valuation, PODD sits about 23% above our discounted-cash-flow fair value (i.e. the DCF flags it as rich).
Is PODD a good stock to buy?
Bull Rankings scores PODD 79.5 out of 100 on its quality-growth model, which is a strong reading. That is driven by Rev (A). A score is a quantitative screen of Insulet Corporation's fundamentals, not personalised financial advice — weigh it against your own time horizon and risk tolerance, and read the risk factors below before acting.
Why does PODD score 79.5 on Bull Rankings?
The quality-growth score blends three pillars — quality (returns on capital, margins, leverage, earnings quality), growth (revenue and earnings expansion), and value (valuation versus sector peers). PODD earns its highest marks on Rev (A). Each pillar is graded against sector-aware thresholds, then combined into the single 0–100 score.
Is PODD overvalued or undervalued?
Based on $158.29, PODD sits about 23% above our discounted-cash-flow fair value (i.e. the DCF flags it as rich). It trades at a 37.0x× P/E (graded C+). Discounted-cash-flow estimates are sensitive to growth and discount-rate assumptions, so treat this as a cross-check, not a price target.
What are the main risks of investing in PODD?
The primary bear case for Insulet centers on its elevated valuation and potential competitive pressures in the rapidly evolving medical device sector. A P/E TTM of 36.8 suggests significant future growth is already priced in, leaving little room for execution missteps or increased competition from alternative insulin delivery systems. The relatively high debt-to-equity ratio of 0.78, while manageable, could become a concern if revenue growth for the Omnipod 5 decelerates faster than anticipated, signaling market saturation or a superior competitive offering.
Bull Rankings is an automated fundamentals screen for research and education. It is not investment advice, and nothing here is a recommendation to buy or sell any security. Do your own research and consider consulting a licensed financial adviser.